Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Multiple Myeloma

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 8, 2010, Pages 1122-1129

  Efebera, Yvonne A ^a   Qureshi, Sofia R ^a   Cole, Suzanne M ^a   Saliba, Rima ^a   Pelosini, Matteo ^a   Patel, Ronak M ^a   Koca, Ebru ^a   Mendoza, Floralyn L ^a   Wang, Michael ^a   Shah, Jatin ^a   Alousi, Amin ^a   Hosing, Chitra ^a   Popat, Uday ^a   Kebriaei, Partow ^a   Anderlini, Paolo ^a   Khouri, Issa F ^a   Champlin, Richard ^a   Giralt, Sergio ^a   Qazilbash, Muzaffar H ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Multiple myeloma; Reduce intensity allogeneic transplant; Relapse refractory

Indexed keywords

BETA 2 MICROGLOBULIN; FLUDARABINE; MELPHALAN;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER GRADING; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER SURVIVAL; ENGRAFTMENT; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; PROGNOSIS; REDUCED INTENSITY CONDITIONING; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; TRANSPLANTATION CONDITIONING; TREATMENT OUTCOME;

EID: 77954311840     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2010.02.015     Document Type: Article

References (37)

1. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
2. Rajkumar S.V., Blood E., Vesole D., et al. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
3. Rajkumar S.V., Jacobus S., Callender N., et al. Randomized phase 111 trial of lenalidomide plus high-dose dexamethasone vs lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood 2006, 108:799. [abstract].
4. Jagannath S., Durie B.G., Wolf J., et al. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. Br J Haematol 2005, 129:776-783.
5. Palumbo A., Falco P., Corradini P., et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA-Italian Multiple Myeloma Network. J Clin Oncol 2007, 25:4459-4465.
6. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111:2516-2520.
7. Koreth J., Cutler C.S., Djulbegovic B., et al. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant 2007, 13:183-196.
8. Kumar A., Kharfan-Dabaja M.A., Glasmacher A., et al. Tandem versus single autologous hematopoietic cell transplantation for the treatment of multiple myeloma: a systematic review and meta-analysis. J Natl Cancer Inst 2009, 101:100-106.
9. Kyle R.A., Rajkumar S.V. Multiple myeloma. Blood 2008, 111:2962-2972.
10. Bensinger W.I. Is there still a role for allogeneic stem-cell transplantation in multiple myeloma?. Best Pract Res Clin Haematol 2007, 20:783-795.
11. Le Blanc R., Montminy-Metivier S., Belanger R., et al. Allogeneic transplantation for multiple myeloma: further evidence for a GVHD-associated graft-versus-myeloma effect. Bone Marrow Transplant 2001, 28:841-848.
12. Reynolds C., Ratanatharathorn V., Adams P., et al. Allogeneic stem cell transplantation reduces disease progression compared to autologous transplantation in patients with multiple myeloma. Bone Marrow Transplant 2001, 27:801-807.
13. Barlogie B., Kyle R.A., Anderson K.C., et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006, 24:929-936.
14. Kuruvilla J., Shepherd J.D., Sutherland H.J., et al. Long-term outcome of myeloablative allogeneic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant 2007, 13:925-931.
15. Bjorkstrand B.B., Ljungman P., Svensson H., et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996, 88:4711-4718.
16. Crawley C., Lalancette M., Szydlo R., et al. Outcomes for reduced-intensity allogeneic transplantation for multiple myeloma: an analysis of prognostic factors from the Chronic Leukaemia Working Party of the EBMT. Blood 2005, 105:4532-4539.
17. Kroger N., Sayer H.G., Schwerdtfeger R., et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002, 100:3919-3924.
18. Champlin R., Khouri I., Anderlini P., et al. Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Bone Marrow Transplant 2001, 27(Suppl 2):S13-S22.
19. Bacigalupo A., Lamparelli T., Barisione G., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006, 12:560-565.
20. Durie B.G., Harousseau J.L., Miguel J.S., et al. International uniform response criteria for multiple myeloma. Leukemia 2006, 20:1467-1473.
21. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
22. Kumar S.K., Therneau T.M., Gertz M.A., et al. Clinical course of patients with relapsed multiple myeloma. Mayo Clin Proc 2004, 79:867-874.
23. von Lilienfeld-Toal M., Hahn-Ast C., Furkert K., et al. A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma. Eur J Haematol 2008, 81:247-252.
24. Dimopoulos M., Spencer A., Attal M., et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007, 357:2123-2132.
25. Weber D.M., Chen C., Niesvizky R., et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007, 357:2133-2142.
26. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498.
27. Corradini P., Cavo M., Lokhorst H., et al. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma. Blood 2003, 102:1927-1929.
28. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
29. Khaled Y., Mellacheruvu S., Reddy P., et al. Long-term outcomes following myeloablative allogeneic transplantation for multiple myeloma compared to autologous transplantation and the impact of graft-versus-myeloma effect. Bone Marrow Transplant 2009, 44:325-326.
30. Rosinol L., Perez-Simon J.A., Sureda A., et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008, 112:3591-3593.
31. Bruno B., Rotta M., Patriarca F., et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007, 356:1110-1120.
32. Garban F., Attal M., Michallet M., et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006, 107:3474-3480.
33. Stewart K. Reduced-intensity allogeneic transplantation for myeloma: reality bites. Blood 2009, 113:3135-3136.
34. Lee C.K., Badros A., Barlogie B., et al. Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003, 31:73-80.
35. Perez-Simon J.A., Martino R., Alegre A., et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003, 121:104-108.
36. Badros A., Barlogie B., Siegel E., et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. J Clin Oncol 2002, 20:1295-1303.
37. de Lavallade H., El-Cheikh J., Faucher C., et al. Reduced-intensity conditioning allogeneic SCT as salvage treatment for relapsed multiple myeloma. Bone Marrow Transplant 2008, 41:953-960.